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Edited by Jesus AvilaAbstract Accumulation in brain of the b-amyloid peptide (Ab)
is considered as crucial pathogenic event causing Alzheimers dis-
ease (AD). Anti-Ab immune therapy is a powerful means for Ab
clearance from the brain. We recently showed that intravenous
injections of anti-Ab antibodies led to reduction, elevation or
no change in brain Ab42 concentrations of an AD mouse model.
We report here, in a second passive immunization protocol, a dif-
ferent bioactivity of same antibodies to alter brain Ab42 concen-
trations. Comparing the bioactivity of anti-Ab antibodies in these
two passive immunization paradigms underscores the potential of
immune therapy for AD treatment and suggests that both the
epitope recognized by the antibody and the mode of antibody
administration are crucial for its biological activity.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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peptide1. Introduction
The b-amyloid peptide (Ab), a cleavage product of the amy-
loid precursor protein (APP), is the primary component of se-
nile plaques and a major player in Alzheimers disease (AD)
pathology [1,2]. AD is an age-related neurodegenerative illness
that is characterized by progressive cognitive deﬁcits such as
memory loss and a decline in mental abilities. High brain Ab
level is associated with impaired synaptic functions and the
loss of neurons [2,3]. Therefore, both active and passive immu-
nization approaches are being tested in experimental and clin-
ical studies to remove Ab from the aﬀected brains (for a review
see [3]).
Anti-Ab immune therapy is shown to reduce the brain Ab
levels in human patients and in AD mouse models that express
high levels of Ab and exhibit an age-dependent AD-like
pathology [4–8]. In addition, anti-Ab immunizations amelio-
rated the cognitive deﬁcits of transgenic mouse models of
AD [9,10] and AD patients [11].Abbreviations: Ab, b-amyloid peptide; AD, Alzheimers disease; APP,
amyloid precursor protein; i.c.v., intracerebro-ventricular
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doi:10.1016/j.febslet.2005.01.002Three mechanisms have been proposed to explain the thera-
peutic potential of the anti-Ab antibodies for the treatment of
AD. These mechanisms include the catalytic conversion
of ﬁbrillar Ab to less toxic forms [6,12,13], the opsonization
of Ab deposits leading to microglial phagocytosis [6,12,14],
and the promotion of the eﬄux of Ab from the brain to the cir-
culation [5]. Evidence exists supporting all three mechanisms,
which are not mutually exclusive. Clinical trials of active
immunization with vaccines against human Ab42 were halted
due to an unacceptable incidence of meningoencephalitic reac-
tions. Alternative strategies to the vaccination of AD patients
with the Ab42 peptide are suggested to be active immunization
with Ab fragments or passive immunization.
Therefore, it is inevitable to investigate whether anti-Ab
antibodies exert a constant bioactivity determined solely by
the recognized epitope or whether the bioactivity of a given
antibody also depends on the administration method. In this
study, the eﬃcacy of intra-ventricular grafting of antibody
producing cells to reduce Ab levels in brain and periphery
was tested. These data are compared to the results obtained
in a parallel experiment subjecting the same AD model to
intravenous injections of same antibodies [15]. Our accumula-
tive data verify the bioactivity of anti-Ab antibodies with two
diﬀerent immunization protocols in vivo. We show that the
eﬃcacy of these antibodies to reduce brain Ab42 levels is
dependent on the epitope recognized by these antibodies and
on the mode of the antibody administration.2. Materials and methods
2.1. Isotyping of the antibodies
Monoclonal anti-Ab antibodies used in this study (Table 1) were
subtyped using the Mouse Monoclonal Antibody Isotyping kit
(Boehringer Mannhein) according to the manufactures instructions.
Brieﬂy, the antibodies were diluted to 1 lg/ml and 150 ll of the
sample was applied to the development tubes containing lyophilised
latex beads, incubated for 30 s and then agitated brieﬂy. The strips
were inserted into the test tubes and the results were interpreted
after 5–10 min.2.2. Intra-ventricular implantation of hybridoma cell clones
Transgenic mice with neuronal expression of the Swedish double
mutation of APP (SwAPP mice) were bred and housed as described
[16] and experiments were performed in accordance to national guide-
lines. Two microliters of the hybridoma cell suspension was injected
into the right lateral ventricle of 6–7 weeks old SwAPP or non-trans-
genic littermates (n = 4–9 per group) according to a stereotaxic mouse
brain atlas [17] and mice were analyzed 1–4 weeks later.blished by Elsevier B.V. All rights reserved.
Table 1
List of anti-Ab monoclonal antibodies used in this study
Antibody Recognized immunogene IgG subtype (light chain)
22C4 Ab(30–42) IgG1 (j)
10G8 Ab(1–17) IgG1 (j)
9G10 Ab(36–42) IgG1 (j)
8G7 Ab(1–40) IgG1 (j)
All antibodies belonged to the IgG1 subtype with the j light chain.
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For analysis of APP processing and measurement of Ab42 concen-
trations in brains, mice were anesthetized and perfused transcardially
with ice-cold PBS. Frontal parts of the brains reaching from the stereo-
taxic coordinates interaural 6–5 were homogenized and subjected to
Western blotting as described [15]. This area lies outside the site of
the brains that were injected with the hybridoma cells, a prerequisite
for the comparability of subsequently determined protein concentra-
tions in the brain. After electrophoresis, blots were probed with anti-
bodies 6E10 (Signet) to detect Ab, 6E10 and C-terminal APP
(Sigma) to study possible alterations of APP processing due to anti-
body treatments. Blots were stripped and probed for b-actin (Abcam)
as a loading control as described [8].
Brain Ab42 concentrations were measured in the same brain homog-
enates by a commercially available kit (Innogenetics) [15,16]. More-
over, concentrations of Ab42 and levels of anti-Ab antibodies were
also determined in sera of mice as previously described [15,16].
2.4. Statistical analysis
Data were collected by investigators blinded to the experimental set-
up and were analyzed by non-parametric Mann–Whitney U test. In all
graphs, means ± S.E.M. are shown.3. Results
The eﬀectiveness of anti-Ab antibodies to reduce the Ab lev-
els in vivo was studied by intracerebro-ventricular (i.c.v.)
implantation of antibody producing hybridoma cells into
SwAPP mice. Hybridoma clones were selected on the basis
of the varying bioactivity of the anti-Ab antibodies in another
passive immunization paradigm infusing intravenously puri-
ﬁed antibodies to age-matched SwAPP littermates [15].
A standard number of hybridoma cells for i.c.v. grafting was
established in preliminary experiments by grafting various cell
numbers of the 22C4 clone into the right ventricle of age-B
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Fig. 1. Intracerebral grafting of anti-Ab-producing hybridoma cells. (A) An
2.5 · 105 cells of clone 22C4 reached a maximum at 1–2 weeks post-grafting
weeks after the i.v.c. implantation of the hybridoma cells. (B) Anti-Ab antibo
the time of perfusion. The values are expressed as fold increase, relative to the
23 aged-matched SwAPP mice that was set as 100%. (C) Ab42 concentration
values are expressed in percent variation, relative to the baseline obtained by
matched, non-implanted SwAPP littermates that was set as 100% (** P 6 0.
levels in brain and serum in the i.c.v. passive immunization paradigm.matched non-transgenic mice. Peripheral antibody titers were
measured by analyzing blood sera before the grafting and at
the time of perfusion (n = 4–5 per group), reﬂecting the values
of brain antibody titers. Anti-Ab antibody titers increased with
the number of implanted cells reaching a maximum at 1–2
weeks after grafting of 2.5 · 105 cells (Fig. 1A), whereas longer
survival times did not lead to higher antibody levels. There-
fore, a time point of three weeks after implantation was chosen
for sacriﬁce of SwAPP mice in order to be close to peak anti-
body concentrations, while at the same time allowing enough
time for possible removal of Ab by the produced antibodies.
Moreover, the duration of three weeks ensured the compara-
bility of this experiment to our previous study, treating age-
matched SwAPP mice with puriﬁed anti-Ab antibodies for
three weeks intravenously [15].
Three weeks after the implantation of the hybridoma cells
serum anti-Ab antibody levels were assessed by analysis
of the blood samples taken at the time of perfusion and were
compared to baseline antibody levels of 23 untreated age-
matched SwAPP littermates (Fig. 1B). At the time of perfu-
sion, all SwAPP mice implanted with the above number of
diﬀerent hybridoma clones showed signiﬁcant elevated anti-
Ab antibody titers when compared to untreated SwAPP litter-
mates (Fig. 1B). Animals implanted with clone 22C4, however,
showed antibody titers roughly sixfold higher compared to
titers assessed for animals implanted with the three other
clones, even though the same number of cells were implanted
(Fig. 1B). This variation may reﬂect the diﬀerences in produc-
tivity of the various hybridoma clones or may be due to a vary-
ing turnover rate of the antibodies in vivo.
Next we assessed whether the intracerebral production of
the antibodies against Ab caused a change of Ab42 concentra-
tions in the CNS and the periphery, and whether the eﬀects
depended on the implanted hybridoma clone. Quantiﬁcation
of the concentrations of Ab42 in the sera and brains of
SwAPP mice implanted with hybridoma cells revealed that
only grafting the hybridoma clone 8G7 reduced the Ab42 con-
centrations, both in the brain and in serum, when compared
to the corresponding levels of untreated age-matched SwAPP
littermates (Fig. 1C, P 6 0.01). In contrast to results obtained
by intravenous administration of these antibodies (Fig. 2), all
other clones did not cause any signiﬁcant changes (Fig. 1C).G7
C
**
**
0
20
40
60
80
100
120
140
22C4 10G8 9G10 8G7
Aβ
42
 le
v
el
s
(%
 
ch
an
ge
 r
el
at
iv
e 
to
 b
a
se
 li
ne
)
Brain
Serum
ti-Ab antibody titers in serum of non-transgenic mice implanted with
and declined thereafter (w1–w4 indicate that serum was prepared 1–4
dy titers in sera of SwAPP mice grafted i.c.v. with hybridoma clones at
baseline value obtained from averaging preimplantation readings from
s in brain homogenates and sera of i.c.v. implanted SwAPP mice. The
averaging the corresponding values from a control group of four age-
01). Note that 8G7 is the only antibody that leads to reduction of Ab
050
100
150
200
250
300
350
400
450
22C4 10G8 9G10 8G7
A
β4
2 
le
v
el
s
(%
 
ch
an
ge
 r
el
at
iv
e 
to
 b
a
se
 li
ne
) Brain
Serum
*
*
***
Fig. 2. (This ﬁgure was reproduced from Mohajeri et al.: Neurode-
generative Diseases 1, 160–167 (2004), with the permission from
S. Karger, AG, Basel, Switzerland). Passive immunization of SwAPP
mice by intravenous injections of puriﬁed antibodies. Mice were
treated with antibodies for three weeks (for application details see
[15]). Ab42 concentrations in brain homogenates and sera are expressed
in percent relative to a 100% baseline of the corresponding values
obtained from averaging readings from a control group of four age-
matched, non-implanted SwAPP littermates (* P 6 0.05,
*** P 6 0.001). While the Ab42 concentrations in serum were not
changed in any group relative to the baseline, Ab42 levels were
unchanged, elevated or reduced in the brains of mice depending on the
utilized antibodies. Note that intravenous infusion of 8G7 leads to an
increase of cerebral Ab levels.
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served may be attributed to diﬀerent IgG subtypes, which are
known to vary in their opsonization capacities. All antibodies
used in this study, however, belong to the same IgG isotype
(Table 1).
Consistent with data obtained for the passive immunization
achieved by intravenous injection of puriﬁed antibodies
[15,16], when compared to untreated brains, no consistent
alterations in APP processing could be detected by Western
blotting in brains of mice involved in the i.c.v. passive immu-
nization paradigm, suggesting that anti-Ab immune therapy
would not interfere with normal APP functions.4. Discussion
The aim of this study was to test the eﬃcacy of several anti-
Ab antibodies to reduce brain Ab42 concentrations in vivo and
compare this bioactivity to the results of a recently published
study using the same antibodies in a conceptually diﬀerent pas-
sive immunization procedure [15].
To compare the eﬃcacy at which Ab42 levels were reduced in
brain or serum of treated mice, Ab42 concentrations were
quantiﬁed by ELISA. Diﬀerent antibodies raised against de-
ﬁned epitopes of the Ab peptide varied in their activity to
mediate Ab clearance from the brain indicating that the kinet-
ics of Ab clearance by monoclonal antibodies depended on the
recognized epitope by the antibody [15]. Because all antibodies
used in this study belong to the same IgG subtype, the ob-
served diﬀerences in the bioactivity of these antibodies cannot
be attributed to diﬀerent opsonization capacity that varies be-
tween the IgG isotypes.
Anti-Ab immune therapy is a powerful means to prevent
amyloid pathology in transgenic mouse models of AD over-
expressing human mutant APP [5–7,9,10,13] and in human
subjects [4]. It is a unresolved issue, however, why some anti-Ab antibodies reduce brain Ab levels without entering the
brain, whereas others are ineﬀective even though they recog-
nize and bind Ab in vitro [5,6].
We tested here whether the bioactivity of antibodies against
Ab may be inﬂuenced by experimental set up. Therefore, in
addition to passive immunization of a mouse model of AD
expressing the SwAPP by intravenous injection of puriﬁed
antibodies (Fig. 2) [15], we set on in this study to evaluate
the bioactivity of the same antibodies by a second passive
immunization protocol; implanting the hybridoma cells secret-
ing same antibodies intra-ventricularly.
The concept of passive immunization has often been tested
in AD mouse models but normally in one experimental par-
adigm [5,6,18], rendering the generalization as to the appli-
cability of certain antibodies very diﬃcult. Our study
therefore aimed, as a ﬁrst step, in testing diﬀerent immuniza-
tion protocols in a mouse model resembling an early stage
of AD pathology. We chose young SwAPP mice without
plaque pathology to assess antibody-mediated changes in
soluble Ab, because of signiﬁcant correlation of soluble Ab
concentrations with the degree of cognitive impairment in
AD patients. Moreover, we were most interested in Ab42 be-
cause it represents the most amyloidogenic Ab species, and
its levels are massively increased in the progression of
pathology in both AD patients and APP transgenic mouse
models [19,20].
Blood samples of treated SwAPP mice were taken at perfu-
sion and assessed for peripheral antibody titers. All mice
showed a signiﬁcant elevation of anti-Ab antibody levels in
their blood indicating that grafted hybridoma cells produce
the antibodies during the course of the study. After i.c.v. graft-
ing of hybridoma cells, signiﬁcant reductions in brain and serum
Ab42 concentrations were observed only in SwAPP mice
implanted with hybridoma clone 8G7. The antibodies pro-
duced by the other three grafted hybridoma clones exerted
no signiﬁcant eﬀect on Ab42 levels in the i.v.c. passive immuni-
zation paradigm, a result that varies considerably from the
outcome of the intravenous passive immunization study [15].
In a previous study, only 8G7 promoted a continuous up-
take of Ab42 by primary microglial cells in vitro [15]. All anti-
bodies used in both studies recognize and bind the
transgenically expressed Ab as was shown by Western blotting
and have facilitated Fc receptor-mediated microglial uptake of
ﬁbrillar Ab42 in vitro [15]. Furthermore, SwAPP mice treated
in both protocols were littermates and the duration of treat-
ment was identical for both immunization protocols. There-
fore, we conclude that the variations of the bioactivity of
these antibodies to reduce cerebral Ab concentrations in one
immunization protocol must be attributed to the epitope they
recognize. More importantly, however, the varying eﬀect of the
same antibody between the two immunization protocols
should be caused by the diﬀerent methods of antibody applica-
tion to the mice.
The absence of an eﬀect on brain levels of soluble Ab can be
explained by the failure of the antibodies to bind Ab eﬀectively
in the periphery and thus exert the eﬀect of a peripheral sink,
or by the inability to induce enhanced microglial uptake of Ab
in the brain [21,22]. Only the 8G7 antibody could reduce the
Ab levels in brain and serum of i.c.v. treated mice. This ﬁnding
is in line with data that mostly antibodies directed against the
midportion of Ab were able to bind the soluble peptide and
prevent its oligomerization and ﬁbrillogenesis [5], and the fact
756 M.N.M. Gaugler et al. / FEBS Letters 579 (2005) 753–756that the above antibodies (except for 8G7) were directed either
against the N- or C-terminal epitopes of Ab.
Moreover, the biological eﬀects of the 8G7 antibody de-
pended on the routes of antibody application. We speculate
that one explanation for this varying bioactivity may be that
the intravenous injection of 8G7 may have changed the
blood–brain barrier permeability for Ab. Because the trans-
port of Ab through the blood–brain barrier is bidirectional
[15], it is possible that the peripheral administration of 8G7
caused a shift of Ab concentrations between the periphery
and the brain. In contrast, following the cerebro-ventricular
production, when 8G7 is produced in the brain, it seems to
be able to interact with Ab and to alter Ab catabolism leading
to a signiﬁcant reduction of Ab levels in the brain and serum
compartments.
Even though the concept of passive immunization was
tested in AD mouse models before, no study has yet com-
pared the consequences of diﬀerent application procedures
on the bioactivity of the same antibodies in vivo. The pres-
ent study, in combination with our recently published results
[15], oﬀers a comparison of diﬀerent strategies for the pas-
sive immunization in a mouse model mimicking AD pathol-
ogy for several anti-Ab antibodies. We show that the
bioactivity of anti-Ab antibodies not only depended on the
epitope recognized, but also on the application mode of
the antibody. A given antibody can exert an eﬀect in one
application strategy, whereas being ineﬀective or exhibiting
opposite eﬀects in another mode of application. These data
emphasize the importance of validation the bioactivity of
anti-Ab therapy in several experimental passive immuniza-
tion set ups prior to use in human subjects. They may be
therefore valuable to prevent side-eﬀects that may accom-
pany future immune therapy strategies against AD.
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